June 7, 2023 in Home Page, NanOlogy Press Release

NanOlogy Presents Clinical Research at 2023 DDW and ASCO Involving its Large Surface Area Microparticle Investigational Drugs

Comments Off on NanOlogy Presents Clinical Research at 2023 DDW and ASCO Involving its Large Surface Area Microparticle Investigational Drugs

NanOlogy Presents Clinical Research at 2023 DDW and ASCO Involving its Large Surface Area Microparticle Investigational Drugs   FORT WORTH, Texas--NanOlogy LLC, a clinical-stage oncolog ...

Read More
March 7, 2023 in Home Page, NanOlogy Press Release

NanOlogy Granted a US Patent for Its Investigational Drugs in Combination with Immune Checkpoint Inhibitors in the Treatment of Cancer

Comments Off on NanOlogy Granted a US Patent for Its Investigational Drugs in Combination with Immune Checkpoint Inhibitors in the Treatment of Cancer

NanOlogy Granted a US Patent for Its Investigational Drugs in Combination with Immune Checkpoint Inhibitors in the Treatment of Cancer Covers intratumoral delivery of certain LSAM investigational ...

Read More
November 11, 2022 in Home Page, NanOlogy Press Release

NanOlogy Completes Enrollment in Phase 2a Trial of Intratumoral LSAM-PTX with SOC in Patients with Nonoperable Lung Cancer

Comments Off on NanOlogy Completes Enrollment in Phase 2a Trial of Intratumoral LSAM-PTX with SOC in Patients with Nonoperable Lung Cancer

NanOlogy Completes Enrollment in Phase 2a Trial of Intratumoral LSAM-PTX with SOC in Patients with Nonoperable Lung Cancer FORT WORTH (November 11, 2022) — NanOlogy LLC, a clinical-stage inte ...

Read More
Post placeholder image
September 6, 2022 in Publications

Drug Delivery and Translational Research : Local Administration of Large Surface Area Microparticle Docetaxel to Solid Carcinomas Induces Direct Cytotoxicity and Immune-mediated Tumoricidal Effects: Preclinical and Clinical Studies

Comments Off on Drug Delivery and Translational Research : Local Administration of Large Surface Area Microparticle Docetaxel to Solid Carcinomas Induces Direct Cytotoxicity and Immune-mediated Tumoricidal Effects: Preclinical and Clinical Studies
Read More
August 6, 2022 in Presentations

DDW 2022 Poster: The Efficacy of Intracystic Injection of Large Surface Area Microparticle Paclitaxel (NanoPac®) in the Management of Intraductal Papillary Mucinous Neoplasms: Results from an Expanded Access Protocol

Comments Off on DDW 2022 Poster: The Efficacy of Intracystic Injection of Large Surface Area Microparticle Paclitaxel (NanoPac®) in the Management of Intraductal Papillary Mucinous Neoplasms: Results from an Expanded Access Protocol
Read More
August 1, 2022 in Home Page, NanOlogy Press Release

NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Large Surface Area Microparticle Docetaxel in High-Risk Non-Muscle Invasive Bladder Cancer

Comments Off on NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Large Surface Area Microparticle Docetaxel in High-Risk Non-Muscle Invasive Bladder Cancer

NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Large Surface Area Microparticle Docetaxel in High-Risk Non-Muscle Invasive Bladder Cancer   FORT WORTH (August 1, 2022) — Na ...

Read More
May 3, 2022 in Home Page, NanOlogy Press Release

NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of its Topical Investigational Drug in the Treatment of Cutaneous Metastases of Breast Cancer

Comments Off on NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of its Topical Investigational Drug in the Treatment of Cutaneous Metastases of Breast Cancer

NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of its Topical Investigational Drug in the Treatment of Cutaneous Metastases of Breast Cancer FORT WORTH, Texas--NanOlogy LLC, a clini ...

Read More
November 9, 2021 in Home Page, NanOlogy Press Release

Improved Resection Rates in Locally Advanced Pancreatic Cancer Following Addition of Intratumoral NanoPac® to Standard of Care

Comments Off on Improved Resection Rates in Locally Advanced Pancreatic Cancer Following Addition of Intratumoral NanoPac® to Standard of Care

Improved Resection Rates in Locally Advanced Pancreatic Cancer Following Addition of Intratumoral NanoPac® to Standard of Care Presentation of Single-Site Clinical Trial Data Analysis at ACG 2021 ...

Read More